Description
5-Amino-1MQ Capsules | NNMT Inhibitor — Metabolic Research
5-Amino-1MQ (5-Amino-1-methylquinolinium) is a cell-permeable, orally bioavailable small molecule that potently inhibits nicotinamide N-methyltransferase (NNMT), an enzyme highly expressed in white adipose tissue. Preclinical studies have reported significant fat mass reduction, increased energy expenditure, and enhanced NAD+ metabolite levels. These capsules (50mg per capsule, 60 capsules) provide standardised dosing for chronic metabolic research protocols.
Mechanism of Action
- NNMT inhibition — blocks methylation of nicotinamide, redirecting methyl groups and increasing SAM (S-adenosylmethionine) availability
- NAD+ pathway activation — elevates NAD+ precursor levels and downstream sirtuin activity
- Adipogenesis suppression — impairs adipocyte differentiation and lipid accumulation in cell models
- Energy expenditure — increases thermogenesis markers and mitochondrial activity in adipose tissue models
Research Areas
5-Amino-1MQ is studied in obesity, metabolic syndrome, NAFLD, and NAD+ biology research. Commonly paired with NAD+ and AICAR in multi-pathway metabolic studies. The capsule format supports longer-duration adipocyte and metabolic adaptation research protocols.
For Research Use Only. Rainbow Peptide supplies this compound exclusively for in vitro and laboratory research purposes. Not for human or veterinary use.
Dr. R. Trammell –
5-Amino-1MQ capsules for our NNMT inhibition and NAD+ biosynthesis research. Content purity >99% by HPLC. Capsule content uniformity excellent. NNMT inhibition assay confirmed expected IC50. Outstanding quality.
C. Ellington –
50mg 5-Amino-1MQ capsules — ideal for our oral NNMT inhibitor research. Content confirmed. COA thorough. Our SAM/methyl metabolism model showed expected enzyme inhibition.
B. Nwosu –
Good 5-Amino-1MQ capsules. Content >98.5%. Capsule uniformity within spec. COA comprehensive. Convenient oral format for NNMT inhibition and adipogenesis research.